MaxCyte Share News (MXCT)

TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

MaxCyte reports strong fourth quarter as full-year revenues fall

(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022.

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples.

EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

MaxCyte flags lower 2023 revenue, flat 2024 growth

(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022.

IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided.

IN BRIEF: MaxCyte chief scientific officer leaves firm

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board.

TRADING UPDATES: Esken's Southend Airport faces further allegations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

MaxCyte's strategic platform licences redeem otherwise modest results

(Alliance News) - MaxCyte Inc on Tuesday said that promising returns from its strategic platform licence program had bolstered its quarterly revenue expectations.

MaxCyte flags uptick in total fourth-quarter revenue

(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.

MaxCyte teams with Singapore-based Lion to support TCR-T cell work

(Alliance News) - MaxCyte Inc on Wednesday said it had signed a strategic platform licence with Lion TCR to promote the latter's T cell receptor-T cell pipeline.

Maher Masoud starts as MaxCyte president, CEO

(Sharecast News) - MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.

TRADING UPDATES: Technology Minerals identifies lithium at Knockeen

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

MaxCyte announces new CEO, updates revenue guidance

(Sharecast News) - Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenue guidance for 2023.